Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma DOI
Zhuo Yu, Jianfeng Guo, Mengying Hu

et al.

ACS Nano, Journal Year: 2020, Volume and Issue: 14(4), P. 4816 - 4828

Published: March 18, 2020

Hepatocellular carcinoma (HCC) resistant to both chemotherapy and immunotherapy is among the deadliest malignancies. Doxorubicin widely used in transarterial HCC can induce immunogenic cell death (ICD), but resulting immunogenicity still weak. We aim seek a strategy for improving efficacy of ICD based on an immunoregulatory drug called icaritin. Icaritin induced mitophagy apoptosis provoke mouse Hepa1-6 human Huh7 cells. A combination icaritin doxorubicin with molar ratio 1:2 played synergistic role induction. The poly lactic-co-glycolic acid (PLGA)-polyethylene glycol (PEG)-aminoethyl anisamide (AEAA) nanoparticle (NP) targeted codelivery remodeled immunosuppressive tumor microenvironment triggered robust immune memory response, which efficiently improved anti-HCC effect at early stage model. In addition, combo PLGA-PEG-AEAA NP together lenvatinib significantly prolonged survival time mice advanced HCC. Collectively, our findings reveal mechanism provide effective immune-based therapeutic

Language: Английский

YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis DOI
Ruize Gao, Ravi Kiran Reddy Kalathur, Mairene Coto‐Llerena

et al.

EMBO Molecular Medicine, Journal Year: 2021, Volume and Issue: 13(12)

Published: Oct. 19, 2021

Language: Английский

Citations

358
mTORC2 Promotes Tumorigenesis via Lipid Synthesis DOI Creative Commons
Yakir Guri, Marco Colombi, Eva Dazert

et al.

Cancer Cell, Journal Year: 2017, Volume and Issue: 32(6), P. 807 - 823.e12

Published: Dec. 1, 2017

Language: Английский

Citations

357
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies DOI
Yun‐Chieh Sung, Pei-Ru Jin, Li‐An Chu

et al.

Nature Nanotechnology, Journal Year: 2019, Volume and Issue: 14(12), P. 1160 - 1169

Published: Nov. 18, 2019

Language: Английский

Citations

357
Inducing and exploiting vulnerabilities for the treatment of liver cancer DOI
Cun Wang, Serena Vegna, Haojie Jin

et al.

Nature, Journal Year: 2019, Volume and Issue: 574(7777), P. 268 - 272

Published: Oct. 2, 2019

Language: Английский

Citations

349
Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma DOI
Zhuo Yu, Jianfeng Guo, Mengying Hu

et al.

ACS Nano, Journal Year: 2020, Volume and Issue: 14(4), P. 4816 - 4828

Published: March 18, 2020

Hepatocellular carcinoma (HCC) resistant to both chemotherapy and immunotherapy is among the deadliest malignancies. Doxorubicin widely used in transarterial HCC can induce immunogenic cell death (ICD), but resulting immunogenicity still weak. We aim seek a strategy for improving efficacy of ICD based on an immunoregulatory drug called icaritin. Icaritin induced mitophagy apoptosis provoke mouse Hepa1-6 human Huh7 cells. A combination icaritin doxorubicin with molar ratio 1:2 played synergistic role induction. The poly lactic-co-glycolic acid (PLGA)-polyethylene glycol (PEG)-aminoethyl anisamide (AEAA) nanoparticle (NP) targeted codelivery remodeled immunosuppressive tumor microenvironment triggered robust immune memory response, which efficiently improved anti-HCC effect at early stage model. In addition, combo PLGA-PEG-AEAA NP together lenvatinib significantly prolonged survival time mice advanced HCC. Collectively, our findings reveal mechanism provide effective immune-based therapeutic

Language: Английский

Citations

332